Supporting Research into Multi-Cancer Early Detection

The East of England Cancer Alliance supported delivery of the NHS-Galleri trial across the northern part of the region, working with NHS partners to provide local access to one of the world's largest studies of multi-cancer early detection.

The trial evaluated the use of the Galleri® multi-cancer early detection blood test, an innovative test designed to identify signals associated with multiple types of cancer from a single blood sample, often before symptoms develop.

The study aimed to understand whether using this type of blood test alongside existing NHS cancer screening programmes could help detect cancers at an earlier stage, when treatment is often more effective and outcomes can be improved.

The NHS-Galleri Trial

The NHS-Galleri trial was a large-scale research study involving hundreds of thousands of participants across England. The study was led by the Cancer Research UK and King's College London Cancer Prevention Trials Unit, in partnership with NHS England and GRAIL, the company that developed the Galleri® test.

Participants were invited to provide blood samples over several years, allowing researchers to evaluate how accurately the test could identify potential cancers and how it could fit within future NHS diagnostic pathways.

Recruitment and testing have now concluded and the study has entered the analysis phase. Researchers are reviewing the data to determine whether multi-cancer early detection testing could play a role in future approaches to cancer diagnosis and population screening.

The East of England's Contribution

The East of England Cancer Alliance is proud to have supported delivery of the study across the region and to have contributed to this nationally significant research programme.

We would like to thank the many local residents who volunteered to take part in the trial. Their participation has helped contribute to one of the most important cancer early diagnosis studies undertaken in the UK and will inform future evidence on whether multi-cancer blood testing can support improved cancer outcomes.

Why This Research Matters

Earlier diagnosis remains one of the most effective ways to improve cancer outcomes.

Research programmes such as the NHS-Galleri trial help explore whether emerging technologies can:

  • Detect cancers before symptoms develop.
  • Increase the proportion of cancers diagnosed at an earlier stage.
  • Improve treatment options and patient outcomes.
  • Complement existing NHS cancer screening programmes.
  • Support delivery of the ambitions set out in the East of England Cancer Alliance Strategy, the National Cancer Plan for England and the NHS 10 Year Health Plan.

The findings from the trial will help inform future decisions about the potential role of multi-cancer early detection technologies within the NHS.

Further Information

For more information about the NHS-Galleri trial and ongoing research, please visit:

Related Videos

The videos below provide further information about:

  • The NHS-Galleri trial and its aims.
  • Why participants chose to take part.
  • The role of Cancer Alliances in supporting delivery.
  • The potential future role of multi-cancer early detection testing within the NHS.